

This is a repository copy of *Imaging denervation in motor neuron disease for future clinical trials: a longitudinal cohort study*.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/129210/</u>

Version: Accepted Version

Proceedings Paper:

Jenkins, T., Alix, J. orcid.org/0000-0001-8391-9749, Rao, G. et al. (8 more authors) (2017) Imaging denervation in motor neuron disease for future clinical trials: a longitudinal cohort study. In: Journal of the Neurological Sciences. World Congress of Neurology (WCN 2017), 16-21 Sep 2017, Kyoto, Japan. https://doi.org/10.1016/j.jns.2017.08.328, 381s . Elsevier , p. 102.

https://doi.org/10.1016/j.jns.2017.08.328

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Imaging denervation in motor neuron disease for future clinical trials: a longitudinal cohort study

T.Jenkins, J Alix, G Rao, N Hoggard, E.O'Brien, K.Baster, M.Bradburn, J.Bigley, C.McDermott, I.Wilkinson, P.Shaw

A Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom

B Royal Hallamshire Hospital, Department of Neurophysiology, Sheffield, United Kingdom

C University of Sheffield, Academic Unit of Radiology, Sheffield, United Kingdom

D University of Sheffield, School of Mathematics and Statistics, Sheffield, United Kingdom

E School of Health and Related Research, Clinical Trials Research Unit, Sheffield, United Kingdom

Background: A key area-of-need in motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) translational research is a tool to objectively track disease progression over short timescales, to reduce duration and cost of clinical trials. Previous studies have focused on the central nervous system.

Objective: To assess the utility of whole-body MRI to quantify muscle denervation longitudinally in patients with MND, as a novel biomarker, and to probe pathophysiological mechanisms in vivo.

Patients and Methods / Material and Methods: In a prospective longitudinal observational cohort study, 29 MND patients and 22 age and sex-matched controls were assessed with clinical measures, electrophysiological motor unit number index (MUNIX) and T2-weighted whole-body muscle MRI, at first presentation to our clinic and four months later. Between-group differences and associations were assessed using multivariable regression models, adjusted for age and gender. Within-subject longitudinal changes were assessed using paired t-tests. Patterns of disease spread were modeled using mixed effects multivariable regression, assessing associations between muscle relative T2 signal and anatomical adjacency to site of clinical onset.

Results: MND patients had higher relative T2 muscle signal than healthy volunteers at baseline (all-regions mean + 30%(95%CI 15-45) p < 0.001), that was associated with greater disability on patient-reported scales (-0.009(-0.001,-0.02),p = 0.023), and greater weakness and lower MUNIX in multiple individual muscles. Relative T2 signal in bilateral tibialis anterior increased over four months in patients (Figure) (right:+10.2%(2.0-18.4),p = 0.017; left:+14.1%(3.4-24.9),p = 0.013). Anatomically contiguous disease spread on MRI was not demonstrated.

Conclusion: Whole-body muscle MRI offers a new approach to the objective assessment of denervation and spread in MND in vivo. Muscles inaccessible to conventional clinical and neurophysiological assessment may be investigated.